Please login to the form below

Not currently logged in
Email:
Password:

Merck appoints new senior vice president

Laszlo Radvanyi joinsthe firm
Merck KGgA

Merck KGgA has appointed Laszlo Radvanyi as senior vice president and head of research in immuno-oncology.

Radvanyi will focus on leading the discovery of oncology therapies that leverage the natural ability of the body's immune system to fight cancer, as well as identifying biomarkers with the aim to deliver personalized treatments for patients.

Before joining Merck KGgA, Radvanyi served as chief scientific officer at Lion Biotechnologies based in Florida where he was responsible for developing new technologies to product next-generation TILs for tumor indications including lung, cervical and breast cancer.

Luciano Rossetti, head of global research and development, said: “We are honoured to have Laszio join Merck KGaA. His vast experience across the field of immuno-oncology research is very impressive.

“His expertise and fresh perspective will add significant value to our early-stage immuno-oncology portfolio including combination and biomarker strategies for avelumab and other clinical candidates, as we endeavour to bring new therapeutic options to patients living with cancer.”

4th November 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics